Headquartered in Fort Myers, FL·Fiscal year ends December·NASDAQ: NEO·neogenomics.com
About Neogenomics
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company specializing in cancer genetics testing and information services.
Its oncology-focused testing menu spans the cancer continuum and includes:
- next-generation sequencing (NGS)
- molecular residual disease (MRD) testing such as RaDaR ST, which now holds three Medicare-covered indications
- other diagnostic and predictive tests
Its customers include oncologists, pathologists, hospital systems, academic medical centers and pharmaceutical firms. Revenue comes mainly from clinical services, which generated about 93% of Q3 2026 revenue. The remainder comes from non-clinical activity, such as pharma services.
The company operates a network of CAP-accredited and CLIA-certified laboratories across the US and a CAP-accredited sample-processing lab in Cambridge, England. It is investing in NovaSeq X sequencing capacity, IT systems and revenue cycle management. It is also expanding commercial payer in-network agreements.
The company is funded partly through convertible senior notes. A planned CEO transition from Tony Zook to Warren Stone takes effect January 4, 2027. Updated